Mereo BioPharma's three largest insider shareholders as of July 24, 2026 are Charles Sermon (General Counsel, 219.06K shares), Christine Ann Fox (Chief Financial Officer, 89.28K shares), John A. Lewicki (Chief Scientific Officer, 78.63K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Michael S Wyzga | - | 25,050 | 0 | 17 Jun, 2024 |
| John A. Lewicki | Chief Scientific Officer | 78,630 | 0 | 16 Sep, 2024 |
| Charles Sermon | General Counsel | 219,061 | 0 | 16 Sep, 2024 |
| Jeremy Bender | - | 0 | 12,550 | 17 Jun, 2024 |
| Christine Ann Fox | Chief Financial Officer | 89,285 | 0 | 16 Sep, 2024 |
| Alexandra Hughes-Wilson | - | 50,475 | 0 | 16 Sep, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Feb, 2026 | Annalisa Jenkins | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Daniel Shames | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Daniel Shames | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Anders Ekblom | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Michael S Wyzga | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Pierre Jacquet | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Jeremy Bender | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Daniel Shames | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Anders Ekblom | Deferred Restricted Stock Units | A | 133,560 | - | 133,560 | D | A |
| 26 Feb, 2026 | Annalisa Jenkins | Deferred Restricted Stock Units | A | 106,848 | - | 106,848 | D | A |
| 26 Feb, 2026 | Daniel Shames | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Jeremy Bender | Deferred Restricted Stock Units | A | 117,533 | - | 117,533 | D | A |
| 26 Feb, 2026 | Daniel Shames | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Daniel Shames | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |